Improved adjuvanting of seasonal influenza vaccines: preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine.
about
Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseasesHarnessing Local Immunity for an Effective Universal Swine Influenza VaccineMVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 virusesPseudotype-based neutralization assays for influenza: a systematic analysis.Globular Head-Displayed Conserved Influenza H1 Hemagglutinin Stalk Epitopes Confer Protection against Heterologous H1N1 Virus.Viral vector-based influenza vaccines.Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 MiceProtective immunity against influenza in HLA-A2 transgenic mice by modified vaccinia virus Ankara vectored vaccines containing internal influenza proteins.The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species.Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice.Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral ChallengeAssessment of the Plasmodium falciparum Preerythrocytic Antigen UIS3 as a Potential Candidate for a Malaria Vaccine.Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses.Novel Bivalent Viral-Vectored Vaccines Induce Potent Humoral and Cellular Immune Responses Conferring Protection against Stringent Influenza A Virus Challenge.Assessment of Antibodies Induced by Multivalent Transmission-Blocking Malaria Vaccines.Clinical Advances in Viral-Vectored Influenza Vaccines
P2860
Q30209342-1320DA08-25A8-4242-B7C6-8F5817568A16Q30234558-AE2F0A44-E240-4DF4-94C0-1B763D950A6CQ30358935-BF8AFD44-B9A0-4063-876F-632B2D45D23AQ30374662-51BF0AB2-61D2-4264-AF8D-3637D0A84F33Q30387031-B8F9AF3A-B9E2-4215-AB00-1459C1E258EDQ30390938-F57AB1D6-D91B-41F5-BA4F-04701D0DA18DQ30392456-1079C852-01F7-495B-B0D2-8D6B1A1CB488Q30397362-11F5BECF-D197-40F9-8FFA-C8FD1BD03504Q35091556-D411D5D4-B0EF-42D8-A2F5-6E0D067BC11BQ35656657-59C1E218-AAE9-47A0-9AE7-C697B5A3DB56Q36104042-DD113665-47BE-4A7E-B95D-09F5AE5D1238Q37669809-C20E2713-B982-4888-BCD1-2030BFFFB362Q37690439-4F8F6F43-DF15-49B4-9861-E443230CED59Q40116170-9E542001-F1ED-4EAF-BED3-08AE9DDE884AQ49730085-FE46DC2D-44BA-4CF4-B7EB-0BC61F21BCD5Q57094631-0BB3AEAA-3227-401E-9B38-E931098FFB36
P2860
Improved adjuvanting of seasonal influenza vaccines: preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Improved adjuvanting of season ...... inactivated influenza vaccine.
@ast
Improved adjuvanting of season ...... inactivated influenza vaccine.
@en
type
label
Improved adjuvanting of season ...... inactivated influenza vaccine.
@ast
Improved adjuvanting of season ...... inactivated influenza vaccine.
@en
prefLabel
Improved adjuvanting of season ...... inactivated influenza vaccine.
@ast
Improved adjuvanting of season ...... inactivated influenza vaccine.
@en
P2093
P2860
P50
P356
P1476
Improved adjuvanting of season ...... inactivated influenza vaccine.
@en
P2093
B Veronica Carr
Bryan Charleston
Caitlin E Mullarkey
Colin Butter
Eleonora Molesti
Eric A Lefevre
Massimiliano Baratelli
Teresa Lambe
P2860
P304
P356
10.1002/EJI.201242922
P407
P577
2013-06-10T00:00:00Z